Dexcel Pharma Technologies Ltd., 10% Owner at Urovant Sciences Ltd. (UROV), bought 16,570 shares at $7.98 ($132K) on 2019-05-20, disclosed to the SEC on 2019-05-22.
Open-market purchase of $132k UROV by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.98 | 8,285 | $66K | 50.0% |
| 2 | $7.98 | 8,285 | $66K | 50.0% |
| Total | $7.98 avg | 16,570 | $132K | 100% |
| Filing → |
| UROV | BUY | 2019-06-19 | $262K | — | Filing → |
| UROV | BUY | 2019-06-14 | $355K | — | Filing → |
| UROV | BUY | 2019-06-11 | $292K | — | Filing → |